Ecs Botanics Holdings Ltd · ASX:ECS
Ecs Botanics — Shareholder Meeting (November 2024)
11 slides from Ecs Botanics's shareholder meeting presentation, Nov 21, 2024
Slide 1: ECS Botanics Holdings Ltd Annual General Meeting 2024
For personal use only A N N U A L G E N E R A L M E E T I N G - 2 0 2 4 ECS Botanics Holdings Ltd A leading organic cultivator and manufacturer of medicinal cannabis ANNUAL GENERAL MEETING ASX : ECS 21 NOVEMBER 2024
Slide 2: Corporate History
Corporate History Rapidly Growing, Profitable Medicinal Cannabis Cultivator. For personal use only Established in 2018 as an ASX-listed company with a Tasmanian-based Food and I N V E S T O R Wellness business Acquired Murray Meds in March 2021, licensed in 2020 Initial focus on extraction but
Slide 3: FY24 Highlights
FY24 Highlights Production in tonnes Diversified Sales Expanding Production For personal use only E Q U I I NT VY E S • Diversified white label and own • Ideally located in NW Victoria FY22 2.8 brand • Licensed to produce 13 tonnes • Export forecast to be 32% of FY23 4.2 • TGA/GMP Pharmaceutical Gra
Slide 4: The Addressable Market
The Addressable Market Cannabis market globally is still in an emerging phase with strong growth potential. 2023 $0.6 For personal use only Australia2 MEDICAL CANNABIS MARKET billion 20.0 Australia I N V E S T O R ($USD Billions) USA $594m 26m $22 Establishing 28.0 Europe Legal Med Cannabis Populati
Slide 5: Track Record of Financial Performance
Track Record of Financial Performance Scaling revenue and earnings. Strong balance sheet. For personal use only Revenue vs COGS EBITDA BALANCE SHEET 30-Jun-24 30-Jun-23 25 4 I N V E S T O R Cash 3.2 2.5 3 20 2 Total Assets 32.9 26.1 1 15 0 Current financial liabilities (3.9) (3.7) P R E S E N T A T
Slide 6: Strategic Roadmap
Strategic Roadmap Delivering on a Clear Strategy to Drive Value. For personal use only 2018-2020 2021-2023 2024-2026 2027-2029 M A Y Developing Capability Focused, Expanding Drive Profitability, Leading Australian and Confidence and Growing Revenue Innovation and Expansion Medicinal Cannabis 2 0 2 4
Slide 7: Strengthened our leadership
Strengthened our leadership Adding significant experience to our team. For personal use only Dr Rachel Swift joins as NED Nicholas Thomas appointed COO Medical Advisory Board established I N V E S T O R • With nearly 20 years of experience in • Nicholas has 25 years of operational • ECS’ Medical Adv
Slide 8: Strong start to FY25
Strong start to FY25 Revenue growth. B2C business building. For personal use only Quarterly revenue of $5.0 million, up 22.0% on pcp and up 11.1% I N V E S T O R on prior quarter (QoQ) Cash receipts of $4.4 million, up 10.0% on pcp and up 7.3% QoQ Entered eight-year exclusive license agreement
Slide 9: Investment Highlights
Investment Highlights Contracted ~ A$60m in 24 months, with further expansion required to meet market demand Expand GMP manufacturing facility to process volumes Scaling revenue For personal use only Constructing 9 new PCE’s to meet licensed production capacity (bringing total PCEs to 26) On
Slide 10: Q&A
E C S B O T A N I C S H O L D I N G S L T D Q&A For personal use only I N V E S T O R P R E S E N T A T I O N 10
Slide 11: Contact Us
E C S B O T A N I C S H O L D I N G S L T D Contact Us For personal use only I N V E S T O R P R E S E N T A T I O N Call us today at Email us at 1300 833 988 info@ecs-botanics.com Investor Relations eric.kuret@automicgroup.com.au VISIT US E C S - B O T A N I C S . C O M ECS BOTANICS HOLDINGS LTD 11
ECS Botanics Holdings — Shareholder Meeting (November 2024) on 6ix